PRMT1 and neoplasm: Indeed, the anti-tumor miR-503 suppressed the progression of HCC by targeting the protein arginine methyltransferase 1 (PRMT1) and the WEE1 G2 Checkpoint Kinase (WEE1) to block EMT in HepG2 cells [166,167].